Knight Therapeutics Inc.
KHTRF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $440 | $572 | $605 | $504 |
| - Cash | $59 | $78 | $112 | $80 |
| + Debt | $76 | $105 | $54 | $49 |
| Enterprise Value | $458 | $599 | $547 | $473 |
| Revenue | $87 | $107 | $88 | $97 |
| % Growth | -18.7% | 21.9% | -9.1% | – |
| Gross Profit | $29 | $45 | $35 | $40 |
| % Margin | 33.2% | 41.8% | 39.6% | 41.7% |
| EBITDA | $13 | -$1 | $13 | $24 |
| % Margin | 15% | -1% | 14.7% | 25.1% |
| Net Income | -$3 | -$13 | $2 | $11 |
| % Margin | -3.1% | -11.8% | 2.5% | 11.1% |
| EPS Diluted | -0.027 | -0.13 | 0.02 | 0.11 |
| % Growth | 79% | -750% | -81.8% | – |
| Operating Cash Flow | $8 | $20 | $4 | $1 |
| Capital Expenditures | -$0 | -$25 | -$4 | -$1 |
| Free Cash Flow | $7 | -$5 | -$0 | $0 |